A 65-center Chinese real-world analysis presented at IMS 2026 reports deep responses with Eque-cel across older, heavily pretreated and high-risk RRMM patients.
OL-101, a novel BCMA/GPRC5D dual-target CAR-T cell therapy, achieved 100% ORR and deep responses in a Phase I study of heavily pretreated R/R multiple myeloma patients, including those with prior CAR-T exposure and extramedullary disease, presented at EHA 2026.
A patient with ultra–high-risk multiple myeloma achieved deep and durable remission after ASCT combined with BCMA CAR-T therapy, maintaining sCR with MRD negativity for more than 18 months, highlighting a promising strategy for overcoming high-risk disease.
CAR-T cell therapy, antibody-drug conjugates (ADCs), and bispecific antibodies are transforming the treatment landscape for multiple myeloma. Discover how these innovative immunotherapies work and the benefits they offer patients with relapsed or refractory disease.
A Phase 1 clinical study demonstrates that dual-target BCMA-CD19 CAR-T therapy (ICG318) can achieve sustained, drug-free remission and significant renal improvement in patients with refractory SLE and lupus nephritis, with follow-up extending up to six years.
As CAR-T therapy reshapes treatment for multiple myeloma worldwide, China is emerging as a key alternative with strong research, lower costs, and faster access.
This real-world case highlights Eque-cel (Fucaso), a fully human BCMA-targeted CAR-T therapy, achieving deep and durable remission in a heavily pretreated multiple myeloma patient following two transplant relapses.
At ASH 2025, IASO Bio presented updated FUMANBA-2 data for equecabtagene autoleucel in high-risk newly diagnosed multiple myeloma, with a 100% ORR, 93.8% sCR rate and 74.5% 24-month PFS.
On November 3, new clinical data were released for a universal BCMA-targeted CAR-T therapy candidate (CT0596) in patients with relapsed/refractory multiple myeloma (R/R MM). The results show favorable preliminary safety
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.